These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 34049724)

  • 21. Trends in buprenorphine dosage and days supplied for new treatment episodes for opioid use disorder, 2010-2019.
    Tilhou AS; Murray E; Wang J; Linas BP; White L; Samet JH; LaRochelle M
    Drug Alcohol Depend; 2023 Nov; 252():110981. PubMed ID: 37839942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.
    Jones CM; McCance-Katz EF
    Addiction; 2019 Mar; 114(3):471-482. PubMed ID: 30194876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term retention in Office Based Opioid Treatment with buprenorphine.
    Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
    J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The case for a medication first approach to the treatment of opioid use disorder.
    Winograd RP; Presnall N; Stringfellow E; Wood C; Horn P; Duello A; Green L; Rudder T
    Am J Drug Alcohol Abuse; 2019; 45(4):333-340. PubMed ID: 31084515
    [No Abstract]   [Full Text] [Related]  

  • 25. Rethinking Opioid Dose Tapering, Prescription Opioid Dependence, and Indications for Buprenorphine.
    Chou R; Ballantyne J; Lembke A
    Ann Intern Med; 2019 Sep; 171(6):427-429. PubMed ID: 31450240
    [No Abstract]   [Full Text] [Related]  

  • 26. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Timing of hepatitis C treatment initiation and retention in office-based opioid treatment with buprenorphine: a retrospective cohort study.
    Geist ML; Radick AC; Tsui JI; Blalock KL; Adwell A; Tamru E; Connolly NC; James JR
    Addict Sci Clin Pract; 2023 May; 18(1):33. PubMed ID: 37231486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trends In Buprenorphine Prescribing By Physician Specialty.
    Wen H; Borders TF; Cummings JR
    Health Aff (Millwood); 2019 Jan; 38(1):24-28. PubMed ID: 30615523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Time to include buprenorphine-naloxone combination in the WHO Model List of Essential Medicines.
    Balhara YP
    J Opioid Manag; 2013; 9(4):237. PubMed ID: 24380101
    [No Abstract]   [Full Text] [Related]  

  • 30. Differences in buprenorphine treatment quality across physician provider specialties.
    Levin JS; Landis RK; Sorbero M; Dick AW; Saloner B; Stein BD
    Drug Alcohol Depend; 2022 Aug; 237():109510. PubMed ID: 35753279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early Discontinuation of Buprenorphine Therapy for Opioid Use Disorder Among Privately Insured Adults.
    Agbese E; Leslie DL; Manhapra A; Rosenheck R
    Psychiatr Serv; 2020 Aug; 71(8):779-788. PubMed ID: 32264801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Office-Based Buprenorphine Treatment: Identifying Factors That Promote Retention in Opioid-Dependent Patients.
    Noe SR; Keller T
    J Addict Nurs; 2020; 31(1):23-29. PubMed ID: 32132421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A naturalistic study of predictors of retention in treatment among emerging adults entering first buprenorphine maintenance treatment for opioid use disorders.
    Dayal P; Balhara YPS
    J Subst Abuse Treat; 2017 Sep; 80():1-5. PubMed ID: 28755768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between buprenorphine/naloxone and high-dose opioid analgesic prescribing in Kentucky, 2012-2017.
    Luu H; Slavova S; Freeman PR; Lofwall M; Browning S; Slade E; Bush H
    Drug Alcohol Depend; 2019 Dec; 205():107606. PubMed ID: 31606590
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine.
    Tsui JI; Mayfield J; Speaker EC; Yakup S; Ries R; Funai H; Leroux BG; Merrill JO
    J Subst Abuse Treat; 2020 Feb; 109():80-85. PubMed ID: 31810594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does the Addition of Naloxone in Buprenorphine/Naloxone Affect Retention in Treatment in Opioid Replacement Therapy?: A Systematic Review and Meta-Analysis.
    Dalton K; Butt N
    J Addict Nurs; 2019; 30(4):254-260. PubMed ID: 31800516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A mixed-methods analysis of patient safety incidents involving opioid substitution treatment with methadone or buprenorphine in community-based care in England and Wales.
    Gibson R; MacLeod N; Donaldson LJ; Williams H; Hibbert P; Parry G; Bhatt J; Sheikh A; Carson-Stevens A
    Addiction; 2020 Nov; 115(11):2066-2076. PubMed ID: 32149443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of Family Medicine Patient Retention in Opioid Medication-Assisted Treatment.
    Justesen K; A Hooker S; Sherman MD; Lonergan-Cullum M; Nissly T; Levy R
    J Am Board Fam Med; 2020; 33(6):848-857. PubMed ID: 33219064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees.
    Wen H; Hockenberry JM; Pollack HA
    JAMA Netw Open; 2018 Sep; 1(5):e182943. PubMed ID: 30646185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.